Stay updated on MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Sign up to get notified when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.

Latest updates to the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision metadata updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.4.3 was added to the history log, and Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 has been removed.SummaryDifference0.1%

- Check60 days agoChange DetectedThis is a minor metadata update: the revisions history shows Revision: v3.4.1, replacing v3.4.0, with no changes to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page history shows Revision v3.3.4 added and Revision v3.3.3 removed.SummaryDifference0.1%

- Check104 days agoChange DetectedThe page history shows an added Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure link, along with a prior Revision: v3.3.2; These are admin-level updates to the page metadata/footer and do not affect study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.